About Us Services Careers FAQ Contact Us 0
Home Medical Devices Pediatric Clinical Trials Market Size, Share & Trends By 2032
Pediatric Clinical Trials Market

Pediatric Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Treatment Studies, Observational Studies), By Therapeutic Areas (Infectious Diseases, Oncology, Autoimmune/Inflammatory Diseases, Respiratory Disorders, Mental Health Disorders, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRMD2704DR
Last Updated : October 23, 2024
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Pediatric Clinical Trials Market Introduction
    2. By Phase
      1. Introduction
        1. Phase By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    3. By Study Design
      1. Introduction
        1. Study Design By Value
      2. Treatment Studies
        1. By Value
      3. Observational Studies
        1. By Value
    4. By Therapeutic Areas
      1. Introduction
        1. Therapeutic Areas By Value
      2. Infectious Diseases
        1. By Value
      3. Oncology
        1. By Value
      4. Autoimmune/Inflammatory Diseases
        1. By Value
      5. Respiratory Disorders
        1. By Value
      6. Mental Health Disorders
        1. By Value
      7. Others
        1. By Value
    1. Introduction
    2. By Phase
      1. Introduction
        1. Phase By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    3. By Study Design
      1. Introduction
        1. Study Design By Value
      2. Treatment Studies
        1. By Value
      3. Observational Studies
        1. By Value
    4. By Therapeutic Areas
      1. Introduction
        1. Therapeutic Areas By Value
      2. Infectious Diseases
        1. By Value
      3. Oncology
        1. By Value
      4. Autoimmune/Inflammatory Diseases
        1. By Value
      5. Respiratory Disorders
        1. By Value
      6. Mental Health Disorders
        1. By Value
      7. Others
        1. By Value
    5. U.S.
      1. By Phase
        1. Introduction
          1. Phase By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      2. By Study Design
        1. Introduction
          1. Study Design By Value
        2. Treatment Studies
          1. By Value
        3. Observational Studies
          1. By Value
      3. By Therapeutic Areas
        1. Introduction
          1. Therapeutic Areas By Value
        2. Infectious Diseases
          1. By Value
        3. Oncology
          1. By Value
        4. Autoimmune/Inflammatory Diseases
          1. By Value
        5. Respiratory Disorders
          1. By Value
        6. Mental Health Disorders
          1. By Value
        7. Others
          1. By Value
    6. Canada
    1. Introduction
    2. By Phase
      1. Introduction
        1. Phase By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    3. By Study Design
      1. Introduction
        1. Study Design By Value
      2. Treatment Studies
        1. By Value
      3. Observational Studies
        1. By Value
    4. By Therapeutic Areas
      1. Introduction
        1. Therapeutic Areas By Value
      2. Infectious Diseases
        1. By Value
      3. Oncology
        1. By Value
      4. Autoimmune/Inflammatory Diseases
        1. By Value
      5. Respiratory Disorders
        1. By Value
      6. Mental Health Disorders
        1. By Value
      7. Others
        1. By Value
    5. U.K.
      1. By Phase
        1. Introduction
          1. Phase By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      2. By Study Design
        1. Introduction
          1. Study Design By Value
        2. Treatment Studies
          1. By Value
        3. Observational Studies
          1. By Value
      3. By Therapeutic Areas
        1. Introduction
          1. Therapeutic Areas By Value
        2. Infectious Diseases
          1. By Value
        3. Oncology
          1. By Value
        4. Autoimmune/Inflammatory Diseases
          1. By Value
        5. Respiratory Disorders
          1. By Value
        6. Mental Health Disorders
          1. By Value
        7. Others
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Phase
      1. Introduction
        1. Phase By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    3. By Study Design
      1. Introduction
        1. Study Design By Value
      2. Treatment Studies
        1. By Value
      3. Observational Studies
        1. By Value
    4. By Therapeutic Areas
      1. Introduction
        1. Therapeutic Areas By Value
      2. Infectious Diseases
        1. By Value
      3. Oncology
        1. By Value
      4. Autoimmune/Inflammatory Diseases
        1. By Value
      5. Respiratory Disorders
        1. By Value
      6. Mental Health Disorders
        1. By Value
      7. Others
        1. By Value
    5. China
      1. By Phase
        1. Introduction
          1. Phase By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      2. By Study Design
        1. Introduction
          1. Study Design By Value
        2. Treatment Studies
          1. By Value
        3. Observational Studies
          1. By Value
      3. By Therapeutic Areas
        1. Introduction
          1. Therapeutic Areas By Value
        2. Infectious Diseases
          1. By Value
        3. Oncology
          1. By Value
        4. Autoimmune/Inflammatory Diseases
          1. By Value
        5. Respiratory Disorders
          1. By Value
        6. Mental Health Disorders
          1. By Value
        7. Others
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Phase
      1. Introduction
        1. Phase By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    3. By Study Design
      1. Introduction
        1. Study Design By Value
      2. Treatment Studies
        1. By Value
      3. Observational Studies
        1. By Value
    4. By Therapeutic Areas
      1. Introduction
        1. Therapeutic Areas By Value
      2. Infectious Diseases
        1. By Value
      3. Oncology
        1. By Value
      4. Autoimmune/Inflammatory Diseases
        1. By Value
      5. Respiratory Disorders
        1. By Value
      6. Mental Health Disorders
        1. By Value
      7. Others
        1. By Value
    5. UAE
      1. By Phase
        1. Introduction
          1. Phase By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      2. By Study Design
        1. Introduction
          1. Study Design By Value
        2. Treatment Studies
          1. By Value
        3. Observational Studies
          1. By Value
      3. By Therapeutic Areas
        1. Introduction
          1. Therapeutic Areas By Value
        2. Infectious Diseases
          1. By Value
        3. Oncology
          1. By Value
        4. Autoimmune/Inflammatory Diseases
          1. By Value
        5. Respiratory Disorders
          1. By Value
        6. Mental Health Disorders
          1. By Value
        7. Others
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Phase
      1. Introduction
        1. Phase By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    3. By Study Design
      1. Introduction
        1. Study Design By Value
      2. Treatment Studies
        1. By Value
      3. Observational Studies
        1. By Value
    4. By Therapeutic Areas
      1. Introduction
        1. Therapeutic Areas By Value
      2. Infectious Diseases
        1. By Value
      3. Oncology
        1. By Value
      4. Autoimmune/Inflammatory Diseases
        1. By Value
      5. Respiratory Disorders
        1. By Value
      6. Mental Health Disorders
        1. By Value
      7. Others
        1. By Value
    5. Brazil
      1. By Phase
        1. Introduction
          1. Phase By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      2. By Study Design
        1. Introduction
          1. Study Design By Value
        2. Treatment Studies
          1. By Value
        3. Observational Studies
          1. By Value
      3. By Therapeutic Areas
        1. Introduction
          1. Therapeutic Areas By Value
        2. Infectious Diseases
          1. By Value
        3. Oncology
          1. By Value
        4. Autoimmune/Inflammatory Diseases
          1. By Value
        5. Respiratory Disorders
          1. By Value
        6. Mental Health Disorders
          1. By Value
        7. Others
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Pediatric Clinical Trials Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. ICON Plc
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Medpace, Inc.
    3. Pharmaceutical Product Development, LLC
    4. Premier Research
    5. QPS Holdings
    6. Pfizer Inc.
    7. The Emmes Company, LLC
    8. IQVIA Inc.
    9. Bristol-Myers Squibb Company
    10. Covance Inc.
    11. Synteract
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global neurology clinical trials market size was valued at USD 5.01 billion in 2021, and is projected to reach USD 8.23 billion by 2030, registering a CAGR of 5.67% from 2022 to 2030.  The field of neuroscience keeps drawing a respectable a
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.